Clinical Trial Detail

NCT ID NCT02321293
Title A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC
Recruitment Unknown status
Gender both
Phase Phase I
Variant Requirements No
Sponsors Lady Davis Institute
Indications

lung non-small cell carcinoma

Therapies

Erlotinib + Gefitinib

Age Groups: adult

No variant requirements are available.